UCL and Francis Crick-founded Achilles has secured $69.9m in its series C round.
Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, secured £52.7m ($69.9m) in a series C round today backed by Syncona.
OrbiMed, Boxer Capital of Tavistock Group, RA Capital Management, Forbion, Invus, Perceptive Advisors and Redmile Group as well as unnamed investors backed the round.
Achilles is working on personalised T cell cancer therapies.
The series C financing will accelerate research and development activities and allow Achilles to expand…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
